Drug Profile
SGN CD48A
Alternative Names: SGN-CD48ALatest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Seattle Genetics
- Developer Seagen
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
- Mechanism of Action Cell death stimulants; Mitosis inhibitors; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Mar 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (IV, Infusion)
- 08 Oct 2020 Seattle Genetics is now called Seagen